Stockscreener 앱 받기
12.21
4.20%
-0.535
시장 영업 전:
12.45
0.245
+2.01%
전일 마감가:
$12.74
열려 있는:
$12.74
하루 거래량:
1.73M
Relative Volume:
1.04
시가총액:
$1.52B
수익:
$181.74M
순이익/손실:
$-599.49M
주가수익비율:
-2.4361
EPS:
-5.01
순현금흐름:
$-604.32M
1주 성능:
-17.14%
1개월 성능:
-35.46%
6개월 성능:
-36.37%
1년 성능:
-56.78%
1일 변동 폭
$12.14
$12.92
1주일 범위
$12.14
$14.79
52주 변동 폭
$12.14
$30.41
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
ARWR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
12.21 | 1.52B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Rnai Technology Market Generated Opportunities, Future Scope - openPR.com
Rnai Technology Market Set to Witness Significant Growth - openPR
Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance
Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
First Capital REIT Announces March 2025 Distribution - The Globe and Mail
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World
Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL.com
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks
Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks
Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com
Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com
Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com
Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com
Familial Chylomicronemia Syndrome Market to Expand - openPR
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Trimmed by Principal Financial Group Inc. - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Galveston County Daily News
How Arrowhead's New FCS Resources Could Transform Life for Rare Disease Patients - Stock Titan
Rhumbline Advisers Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Objective long/short (ARWR) Report - Stock Traders Daily
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - The Bakersfield Californian
Can Arrowhead's New Obesity Drug Outperform GLP-1s? Preclinical Data Shows Key Advantage - Stock Titan
Van ECK Associates Corp Raises Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Empowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Fat, not muscle: drugmakers in race for next weight-loss breakthrough - Reuters
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
B. Riley Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.89%
0.13%
자본화:
|
볼륨(24시간):